Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lorus Therapeutics has received a patent allowance in the US, covering the composition of matter of its lead antimicrobial compound LOR-220 and related small molecules.
Subscribe to our email newsletter
LOR-220 is a small molecule that targets a class of novel bacterial proteins called kinases, which have recently emerged as critical signaling molecules in bacteria
The patent also provides Lorus with patent protection for antimicrobial compositions based on LOR-220 for inhibiting growth of a variety of drug-resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
Lorus has issued patents for LOR-220 in Australia and China, as well as pending patents for this compound in other countries worldwide.